英基 IMGN 深 滬
交易中 08-21 11:30:13 美东时间
31.23
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 31.23
- 總市值 777.63万
- 52周最高 31.25
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.605
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 31.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.51
- 每 手 1
- 風險率 6.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics, Inc. has appointed Alejandra Carvajal as its new Chief Legal Officer. With over two decades of legal experience in the biotechnology sector, Carvajal will support the company's strategic and operational initiatives. She previously served as Chief Legal Officer at Mersana Therapeutics and Momenta Pharmaceuticals. CytomX, a clinical-stage oncology-focused biopharmaceutical company, is advancing its PROBODY® therapeutic platform...
08-03 12:00
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CytomX Therapeutics announced it will report second quarter financial results on August 6, 2026, followed by a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the webcast via the company’s website or register for the call in advance. The company, focused on developing conditionally activated biologics for cancer treatment, highlights its pipeline including varsetatug masetecan (Varseta-M) and CX-801. CytomX col...
07-30 12:00
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis
• Skyrizi and Rinvoq growth offset revenue losses from Humira biosimilar competition. • AbbVie raised its full-year adjusted earnings guidance following strong quarterly results. • Positive late-stage clinical trial data in neuroscience and oncology boosted mid-term growth.
07-28 15:15
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?
• Positive clinical trial outcomes for Skyrizi and Rinvoq bolster AbbVie’s post-Humira growth strategy. • Institutional investors favor AbbVie for its robust dividend profile and resilient cash flows. • Investment banks recently raised long-term forecasts citing improved margins and reduced pricing concerns.
07-16 15:15
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX and Regeneron expand their collaboration to develop next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms. CytomX receives $37 million for two additional targets, with Regeneron having the option to select up to 6 more, potentially reaching $4 billion in milestones. The partnership aims to enhance cancer treatments with conditionally-activated therapies, minimizing off-target effects and ad...
06-03 12:00
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy to advance its PROBODY® pipeline, including the lead program Varseta-M, toward potential commercialization. With over 25 years of experience in regulatory affairs, Dr. Gokhale joins CytomX as it prepares for key regulatory interactions, particularly for Va...
05-18 12:00
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology appoints Nelson Azoulay as Chief Business Officer. With over 15 years of experience in corporate strategy and biopharma transactions, Azoulay will lead corporate development and advance MICVO, the company's lead ADC targeting EDB+FN in solid tumors. MICVO is in Phase 1/2 trials for recurrent/metastatic head and neck cancer and has received FDA Fast Track Designation. Azoulay's expertise in ADCs and strategic transactions is expecte...
05-07 20:05
